Bioheart, Inc. Announces World's First Combination Stem Cell Treatment
Bioheart Announces World's First Combination Stem Cell Treatment
SUNRISE, FL--(Marketwired - Jul 24, 2014) - Bioheart, Inc. (OTCQB: BHRT) announced today that it has completed the world's first combination stem cell treatment with Magnum Cell Therapies (Magnum) in Honduras. A patient with congestive heart failure has been treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath® Catheter.
The patient was treated at the Honduras Medical Center (http://www.hmc.com.hn/index.php?page=main) with Managing Director Dr. Ricardo Aguilar. The procedure was led by cardiologists Dr. Haroldo Lopez and Dr. Raul Marenco.
Kristin Comella, Bioheart's Chief Scientific Officer, attended the case and said, "We are bringing new regenerative therapies to many patients around the world. We believe that this new method of cell combination is the best therapy available to patients suffering from heart failure."
"Magnum has brought cutting edge regenerative therapies to Honduras," said Dr. Rene Fiallos, Magnum's Chief Medical Officer. "We are seeing excellent results so far with stem cell therapy and we are thrilled to expand our services."
About Bioheart, Inc.
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
About Magnum Cell Therapies
Magnum Cell Therapies is committed to providing individualized professional service to our patients by promoting self-healing. We strive to improve our patient's health through autologous stem cell therapy and other regenerative medicine technologies. Our goal is to utilize the world's most advanced technologies and help to change the course of medicine with natural techniques. For more information on Magnum, visit www.magnumterapiacelular.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
Contact:
Media
Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 772.285.8511
cmatton@bioheartinc.com
Help employers find you! Check out all the jobs and post your resume.